Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group

Randomised multicentre phase III study comparing weekly versus every-3-week carboplatin plus paclitaxel in patients with advanced ovarian cancer: the MITO-7 (Multicentre Italian Trials in Ovarian cancer) -ENGOT-OV-10 (European Network of Gynaecological Oncological Trial Groups) -GCIG (Gynecologic Cancer InterGroup) trial.

Sandro Pignata
Giovanni Scambia
Dionyssios Katsaros
Ciro Gallo
Eric Pujade- Lauraine
Sabino De Placido
Alessandra Bologna
Beatrice Weber
Francesco Raspagliesi
Pierluigi Benedetti Panici
Gennaro Cormio
Roberto Sorio
Maria Giovanna Cavazzini
Gabriella Ferrandina
Enrico Breda
Viviana Murgia
Cosimo Sacco
Saverio Cinieri
Vanda Salutari
Caterina Ricci
Carmela Pisano
Stefano Greggi
Rossella Lauria
Domenica Lorusso
Claudia Marchetti
Luigi Selvaggi
Simona Signoriello
Maria Carmela Piccirillo
Massimo Di Maio
Francesco Perrone

January 2014

BACKGROUND: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemothera...

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study

PIGNATA S
BREDA E
SCAMBIA G
PISANO C
ZAGONEL V
LORUSSO D
GREGGI S
DE VIVO R
FERRANDINA G
PERRONE F.
GALLO, Ciro

January 2008

Background: Carboplatin/paclitaxel every 3 weeks is the standard for patients with ovarian cancer, b...

The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study

Cadron, Isabelle
Abdulkadir, Leyla
Despierre, Evelyn
Berteloot, Patrick
Neven, Patrick
Leunen, Karin
Amant, Frédéric
Vergote, Ignace

January 2013

Objective. To evaluate the "Leuven" weekly paclitaxel/carboplatinum (TC) regimen in recurrent ovaria...

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group

Vergote, Ignace
Debruyne, Philippe
Kridelka, Frédéric
Berteloot, Patric
Amant, Frédéric
Honhon, Brigitte
Lybaert, Willem
Leunen, Karin
Geldhof, Kurt
Verhoeven, Didier
Forget, Frédéric
Vuylsteke, Peter
D'Hondt, Lionel
Huizing, Manon
Van Den Bulck, Heidi
Laenen, Annouschka

January 2015

Objective To investigate the addition of prophylactic G-CSF to each weekly paclitaxel/carboplatin co...

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel

Hoskins, P
Vergote, Ignace
Cervantes, A
Tu, D
Stuart, G
Zola, P
Poveda, A
Provencher, D
Katsaros, D
Ojeda, B
Ghatage, P
Grimshaw, R
Casado, A
Elit, L
Mendiola, C
Sugimoto, A
D'Hondt, V
Oza, A
Germa, J R
Roy, M
Brotto, L
Chen, D
Eisenhauer, E A

October 2010

Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a no...

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study

Fleming, Gini F.
Fowler, Jeffrey M.
Waggoner, Stephen E.
Copeland, Larry J.
Greer, Benjamin E.
Horowitz, Ira
Sutton, Gregory
Schilder, Russell J.
Fracasso, Paula M.
Ball, Harrison G., III
McGuire, William P., III

February 2001

PURPOSE: The primary objective of this phase I trial was to determine the feasibility of administeri...

Clinical Trial Note A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Keiichi Fujiwara
Eriko Aotani
Tetsutaro Hamano
Shoji Nagao
Hiroyuki Yoshikawa
Toru Sugiyama
Junzo Kigawa
Daisuke Aoki
Noriyuki Katsumata
Masahiro Takeuchi
Mitsuaki Suzuki

January 2010

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intrape...

Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life

Brotto, Lori
Brundage, Michael
Hoskins, Paul
Vergote, Ignace
Cervantes, Andres
Casado, Herraez A
Poveda, A
Eisenhauer, Elizabeth
Tu, Dongsheng

March 2016

A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) ...

Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

Vandenput, Ingrid
Vergote, Ignace
Neven, Patrick
Amant, Frédéric

January 2012

Objective: The objective of the study was to evaluate the response of weekly paclitaxel/carboplatin ...

Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial

Hanan Shawky
Hesham Tawfik
Medhat Hewidy

September 2014

Purpose: The aim of this study was to investigate efficacy and toxicity of the dose-dense weekly pac...

Original article Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer:

Masaaki Kawashima
Hajime Kondo

August 2016

Objective: The aim of the present study was to investigate the dif-ferences between therapeutic gran...

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

Rose, Peter G.
Blessing, John A.
Ball, Harrison G., III
Hoffman, James
Warshal, David
DeGeest, Koen
Moore, David H.

February 2003

OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity ...

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

Harries, M
Moss, C
Perren, T
Gore, M
Hall, G
Everard, M
A'Hern, R
Gibbens, I
Jenkins, A
Shah, R
Cole, C
Pizzada, O
Kaye, S

August 2004

A total of 53 women with chemotherapy-naý¨ve stage Ic-IV ovarian cancer were treated with four cycle...

A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer

Keiichi Fujiwara
Eriko Aotani
Tetsutaro Hamano
Shoji Nagao
Hiroyuki Yoshikawa
Toru Sugiyama
Junzo Kigawa
Daisuke Aoki
Noriyuki Katsumata
Masahiro Takeuchi
Mitsuaki Suzuki

September 2016

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intrape...

V. Hess
M. W. Verrill
C. C. Bomphray
M. M. Vaughan
M. Allen
M. E. Gore

January 2002

carboplatin–paclitaxel causes toxicity. Toxicity can be reduced by weekly administration. We examine...

Randomised multicentre phase III study comparing weekly versus every-3-week carboplatin plus paclitaxel in patients with advanced ovarian cancer: the MITO-7 (Multicentre Italian Trials in Ovarian cancer) -ENGOT-OV-10 (European Network of Gynaecological Oncological Trial Groups) -GCIG (Gynecologic Cancer InterGroup) trial.

Sandro Pignata
Giovanni Scambia
Dionyssios Katsaros
Ciro Gallo
Eric Pujade- Lauraine
Sabino De Placido
Alessandra Bologna
Beatrice Weber
Francesco Raspagliesi
Pierluigi Benedetti Panici
Gennaro Cormio
Roberto Sorio
Maria Giovanna Cavazzini
Gabriella Ferrandina
Enrico Breda
Viviana Murgia
Cosimo Sacco
Saverio Cinieri
Vanda Salutari
Caterina Ricci
Carmela Pisano
Stefano Greggi
Rossella Lauria
Domenica Lorusso
Claudia Marchetti
Luigi Selvaggi
Simona Signoriello
Maria Carmela Piccirillo
Massimo Di Maio
Francesco Perrone

January 2014

BACKGROUND: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemothera...

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study

PIGNATA S
BREDA E
SCAMBIA G
PISANO C
ZAGONEL V
LORUSSO D
GREGGI S
DE VIVO R
FERRANDINA G
PERRONE F.
GALLO, Ciro

January 2008

Background: Carboplatin/paclitaxel every 3 weeks is the standard for patients with ovarian cancer, b...

The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study

Cadron, Isabelle
Abdulkadir, Leyla
Despierre, Evelyn
Berteloot, Patrick
Neven, Patrick
Leunen, Karin
Amant, Frédéric
Vergote, Ignace

January 2013

Objective. To evaluate the "Leuven" weekly paclitaxel/carboplatinum (TC) regimen in recurrent ovaria...

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group

Vergote, Ignace
Debruyne, Philippe
Kridelka, Frédéric
Berteloot, Patric
Amant, Frédéric
Honhon, Brigitte
Lybaert, Willem
Leunen, Karin
Geldhof, Kurt
Verhoeven, Didier
Forget, Frédéric
Vuylsteke, Peter
D'Hondt, Lionel
Huizing, Manon
Van Den Bulck, Heidi
Laenen, Annouschka

January 2015

Objective To investigate the addition of prophylactic G-CSF to each weekly paclitaxel/carboplatin co...

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel

Hoskins, P
Vergote, Ignace
Cervantes, A
Tu, D
Stuart, G
Zola, P
Poveda, A
Provencher, D
Katsaros, D
Ojeda, B
Ghatage, P
Grimshaw, R
Casado, A
Elit, L
Mendiola, C
Sugimoto, A
D'Hondt, V
Oza, A
Germa, J R
Roy, M
Brotto, L
Chen, D
Eisenhauer, E A

October 2010

Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a no...

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study

Fleming, Gini F.
Fowler, Jeffrey M.
Waggoner, Stephen E.
Copeland, Larry J.
Greer, Benjamin E.
Horowitz, Ira
Sutton, Gregory
Schilder, Russell J.
Fracasso, Paula M.
Ball, Harrison G., III
McGuire, William P., III

February 2001

PURPOSE: The primary objective of this phase I trial was to determine the feasibility of administeri...

Clinical Trial Note A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Keiichi Fujiwara
Eriko Aotani
Tetsutaro Hamano
Shoji Nagao
Hiroyuki Yoshikawa
Toru Sugiyama
Junzo Kigawa
Daisuke Aoki
Noriyuki Katsumata
Masahiro Takeuchi
Mitsuaki Suzuki

January 2010

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intrape...

Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life

Brotto, Lori
Brundage, Michael
Hoskins, Paul
Vergote, Ignace
Cervantes, Andres
Casado, Herraez A
Poveda, A
Eisenhauer, Elizabeth
Tu, Dongsheng

March 2016

A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) ...

Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

Vandenput, Ingrid
Vergote, Ignace
Neven, Patrick
Amant, Frédéric

January 2012

Objective: The objective of the study was to evaluate the response of weekly paclitaxel/carboplatin ...

Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial

Hanan Shawky
Hesham Tawfik
Medhat Hewidy

September 2014

Purpose: The aim of this study was to investigate efficacy and toxicity of the dose-dense weekly pac...

Original article Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer:

Masaaki Kawashima
Hajime Kondo

August 2016

Objective: The aim of the present study was to investigate the dif-ferences between therapeutic gran...

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

Rose, Peter G.
Blessing, John A.
Ball, Harrison G., III
Hoffman, James
Warshal, David
DeGeest, Koen
Moore, David H.

February 2003

OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity ...

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

Harries, M
Moss, C
Perren, T
Gore, M
Hall, G
Everard, M
A'Hern, R
Gibbens, I
Jenkins, A
Shah, R
Cole, C
Pizzada, O
Kaye, S

August 2004

A total of 53 women with chemotherapy-naý¨ve stage Ic-IV ovarian cancer were treated with four cycle...

A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer

Keiichi Fujiwara
Eriko Aotani
Tetsutaro Hamano
Shoji Nagao
Hiroyuki Yoshikawa
Toru Sugiyama
Junzo Kigawa
Daisuke Aoki
Noriyuki Katsumata
Masahiro Takeuchi
Mitsuaki Suzuki

September 2016

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intrape...

V. Hess
M. W. Verrill
C. C. Bomphray
M. M. Vaughan
M. Allen
M. E. Gore

January 2002

carboplatin–paclitaxel causes toxicity. Toxicity can be reduced by weekly administration. We examine...

Randomised multicentre phase III study comparing weekly versus every-3-week carboplatin plus paclitaxel in patients with advanced ovarian cancer: the MITO-7 (Multicentre Italian Trials in Ovarian cancer) -ENGOT-OV-10 (European Network of Gynaecological Oncological Trial Groups) -GCIG (Gynecologic Cancer InterGroup) trial.

Sandro Pignata
Giovanni Scambia
Dionyssios Katsaros
Ciro Gallo
Eric Pujade- Lauraine
Sabino De Placido
Alessandra Bologna
Beatrice Weber
Francesco Raspagliesi
Pierluigi Benedetti Panici
Gennaro Cormio
Roberto Sorio
Maria Giovanna Cavazzini
Gabriella Ferrandina
Enrico Breda
Viviana Murgia
Cosimo Sacco
Saverio Cinieri
Vanda Salutari
Caterina Ricci
Carmela Pisano
Stefano Greggi
Rossella Lauria
Domenica Lorusso
Claudia Marchetti
Luigi Selvaggi
Simona Signoriello
Maria Carmela Piccirillo
Massimo Di Maio
Francesco Perrone

January 2014

BACKGROUND: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemothera...

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study

PIGNATA S
BREDA E
SCAMBIA G
PISANO C
ZAGONEL V
LORUSSO D
GREGGI S
DE VIVO R
FERRANDINA G
PERRONE F.
GALLO, Ciro

January 2008

Background: Carboplatin/paclitaxel every 3 weeks is the standard for patients with ovarian cancer, b...

The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study

Cadron, Isabelle
Abdulkadir, Leyla
Despierre, Evelyn
Berteloot, Patrick
Neven, Patrick
Leunen, Karin
Amant, Frédéric
Vergote, Ignace

January 2013

Objective. To evaluate the "Leuven" weekly paclitaxel/carboplatinum (TC) regimen in recurrent ovaria...

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group

Abstract

Extracted data

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group

Abstract

Extracted data

Related items

Related items